Physician profile
Marie Ott
NPI 1639835317
$4,528.25
in general payments reported to CMS, 2019-2025
22 companies · $747 in 2025
The $747 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $877 · 2023: $1,398 · 2024: $1,507 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,651.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,486.06 | 2022-2025 | |
| Corium, LLC | $634.73 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $450.47 | 2022-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $427.66 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $369.32 | 2025 | Fanapt |
| Axsome Therapeutics, INC. | $318.29 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $215.82 | 2022-2025 | Invega Sustenna, Spravato |
| Tris Pharma INC | $111.78 | 2022-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $102.61 | 2023-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $88.77 | 2023-2024 | Rexulti, Abilify Maintena |
| Collegium Pharmaceutical, INC. | $85.56 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $52.35 | 2022-2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $31.56 | 2025 | Uzedy |
| Dexcom, INC. | $22.68 | 2025 | Dexcom G6 Transmitter |
| Alkermes, INC. | $20.50 | 2023 | Aristada, Lybalvi |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $17.29 | 2025 | Gvoke Hypopen |
| Vertical Pharmaceuticals, LLC | $16.90 | 2024 | Relexxii |
| Tempus Ai, INC | $16.62 | 2024 | |
| Sage Therapeutics, LLC | $16.50 | 2025 | Zurzuvae |
| Neos Therapeutics, LP | $16.29 | 2022 | |
| Abbott Laboratories | $13.72 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $12.77 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Ott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.